|
|
Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial
Arnaud Pigneux
,
Marie Béné
,
Louis-Rachid Salmi
,
Pierre-Yves Dumas
,
Jacques Delaunay
et al.
Journal articles
hal-02874606v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study
Laetitia Largeaud
,
Pascale Cornillet-Lefebvre
,
Jean-François Hamel
,
Pierre-Yves Dumas
,
Naïs Prade
et al.
Journal articles
hal-03441014v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial
Anne Bouvier
,
Jean-Francois Hamel
,
Jacques Delaunay
,
Eric Delabesse
,
Pierre-Yves Dumas
et al.
Journal articles
hal-03604930v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study
Arnaud Pigneux
,
Marie C Béné
,
Philippe Guardiola
,
Christian C Recher
,
Jean-Francois Hamel
et al.
Journal articles
inserm-01480651v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Prospective, Multicentric Phase II Randomized Trial Comparing the Efficacy of Methotrexate or Cyclophosphamide in Large Granular Lymphocytic Leukemia: A French National Study. Report on the Interim Analysis
T. Lamy
,
C. Pastoret
,
R. Houot
,
Loic Ysebaert
,
M. Hunault
et al.
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.1545, 2019, Blood
Conference poster
hal-02427556v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Central Nervous System Involvement in Chronic Lymphocytic Leukemia: Diagnosis and Treatment in a Retrospective Cohort of Thirty Patients
Anne Wanquet
,
Rudy Birsen
,
Sylvain Choquet
,
Vincent Levy
,
Jehan Dupuis
et al.
Blood, 2015, 126 (23), pp.2948
Journal articles
hal-01290433v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party
Johannes Schetelig
,
Patrice Chevallier
,
Michel van Gelder
,
Jennifer Hoek
,
Olivier Hermine
et al.
Journal articles
hal-03440115v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
L’ajout de la lomustine bénéficie aux leucémies myéloïdes aiguës du sujet âgé avec cytogénétique non-défavorable et d’un profil moléculaire à haut risque de l’European Leukemia Net 2017
L. Largeaud
,
P. Cornillet-Lefebvre
,
J.F. Hamel
,
P.Y. Dumas
,
N. Prade
et al.
40e Congrès de la Société Française d’Hématologie, Sep 2020, Paris, France. 26 (S4), pp.64, 2020, Hématologie
Conference poster
hal-02945560v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Addition of Lomustine (CCNU) to Induction and Post-Remission Chemotherapy for Fit Elderly AML Patients without Unfavorable Cytogenetics: Results of the Lamsa-2007 Goelams Trial
Arnaud Pigneux
,
Christian Récher
,
Marie C. Bene
,
Julien Asselineau
,
Ariane C. Mineur
et al.
Blood, 2015, 126 (23)
Journal articles
hal-01295674v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies
Lionel Adès
,
Thomas Prebet
,
Aspasia Stamatoullas
,
Christian Recher
,
Romain Guiéze
et al.
Journal articles
hal-01655899v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|